1. ArTiMist™ Clinical Trial Results By Mr Calvin Ross Sofitel Wentworth Hotel Sydney 14 April 2008 Eastland Medical Systems Ltd

2. Eastland Medical Systems Norwich Facility

3. Eastland Medical Systems Norwich Facility

4. Eastland Medical Systems Norwich Facility

5. Eastland Medical Systems Facility Norwich Facility

6. Eastland Medical Systems Malaria Focus-Mission   Produce a Product suitable for the treatment of Malaria in Infants and Young Children   To conduct Studies in South Africa and Malaysia   To conduct Clinical trials in Africa and Asia   To Produce a Stable Commercial Product

7. Eastland Medical Systems Malaria Facts  500 million cases reported annually  200 million of these are children  Most deaths in Children are aged “Under 5.”  Most Deaths in Africa!  Over 40% of the planet population exposed  Malaria on the increase due to global changes in weather and temperature

8. Eastland Medical Systems Malaria Reality in Infants  Fever  Dehydration  Vomiting  Diarrhoea  Poor nutrition  Comatose  Death

9. Eastland Medical Systems Current Treatments 1.Oral Tablets and Syrups 2.Injections 3.Suppository 4.ACT’s or Combined Treatments 5.Others

10. Eastland Medical Systems Sublingual Spray Product  Multi dose pack  50 dose pack  Approved Materials  Api (DMF in place)  Analytical methods in place  Stable formulation

11. Eastland Medical Systems Sublingual Advantage - ArTiMist™ Main Points  Easy to administer  No drug to swallow  Rapid absorption  Avoids first pass effect  Single multi dose pack  Can be used in remote areas  Simple training required  Easy to store  Improved bio availability ?

12. Eastland Medical Systems Manufacture of Product  Phase I material will be manufactured in Licensed premises in the UK  Clinical phase manufacture UK  Commercial phase UK & Germany  Full production Germany

13. Eastland Medical Systems Phase I studies  Clinical studies: Conducted in South Africa and Malaysia  Single dose study in Malaysia and a multi dose study in South Africa  Clinics located in both regions  Completed March 2008

14. Eastland Medical Systems Phase I Study Results  A Phase I open labelled Randomized trial to determine the Pharmacokinetics, bioequivalence and relative bio availability of Artemether when administrated as a 3mg/actuation sublingual spray, 6mg/actuation sublingual spay and oral tablets in 16 healthy male subjects.  Results showed the sublingual route has higher bio availability when compared to the oral route.  Artemether sublingual spray 3mg strength and 6mg strength are equivalent when given at the same total dose.  Cmax of Artemether and Dihydroartemisinin has proven dose proportionality.  Overall, Artemether delivered as a sublingual spray is as safe and as well tolerated as the oral route.

15. Eastland Medical Systems Clinical Programme Requirement  Regulatory – Technical Brief  Trial requirements in a single/multi dose study  Phase I - 32 subjects  Phase III – 300 patients  Toxicity data exists (in public domain) 1. Literature only required 2. No further animal studies 3. Local toleration study required  Pump spray delivery system  Back up requirements in place  Drug Master File in place

16. Eastland Medical Systems The Conclusion for ArTiMist™  Superior to Tablet Formulation  Stable Formulation  Dose Proportional  No side effects during trials  Fit For Purpose !